HistoSonics

HistoSonics is a privately held medical device company that has developed a non-invasive therapy platform based on the science of histotripsy. Its primary product, the Edison® System, uses pulsed sound energy to destroy tumors at the sub-cellular level without incisions or needles, while allowing physicians to monitor treatment effects in real time. The platform received FDA De Novo clearance for the treatment of liver tumors in October 2023.

The company's technology represents a convergence of histotripsy, ultrasound therapy, and non-invasive tumor treatment. HistoSonics was acquired for $2.25 billion, a valuation that reflects the clinical significance of its approach to oncology. The company operates from locations in Ann Arbor, Michigan, and Minneapolis, Minnesota.

In 2026, TIME recognized HistoSonics as one of its 10 Most Influential Companies in Health & Life Sciences. The company sits at the intersection of the medical devices and healthcare sectors, with a specific focus on developing new treatment modalities for cancer care.